Farmas USA

Grafica ARIA se mira bastante bien !!

Ventas subiendo los ultimos 3 trimestres

https://www.google.com/finance?q=NASDAQ:ARIA&fstype=ii&ei=8R_DUoiYBaiTiAK9SQ

solo que le tengo miedo, PAVOR a valores opcionables

Valores opcionables? Te refieres a "opciones"???

Para mi ARIA es ventas de producto , precio a 20$
FDA abre la bocaza y suspende el producto, precio 2$
FDA recula y permite de nuevo la venta ( con restricciones) ... Precio 7$ y por ahora ...

Voy a por los 10-12

Ranking de farmas Forbes de 2013

http://www.forbes.com/sites/matthewherper/2013/12/31/grading-pharma-in-2013-16-drug-companies-ranked/?partner=yahootix

De todas esas anda que no me gusta NVO ...

Las sorpresas de la FDA (un ejemplo para los creyentes en AMRN)

Christmas has arrived early for United Therapeutics. The biotech ($UTHR) took most analysts completely by surprise with the news that the FDA had stamped an approval on Orenitram (treprostinil, or oral Remodulin) after twice snubbing its application for the pulmonary arterial hypertension drug.

"Recall that the FDA had rejected this drug TWICE before and, with NO ADDITIONAL DATA, $UTHR filed for a third time earlier this year," notes an excited Mark Schoenebaum at ISI, who also called the approval "one of the top 10 biggest upside surprises in the history of the biotech sector... Amazingly, the FDA approved the application. This was CLEARLY outside my base case expectation as well as the Street's."

Investors quickly took the hint and drove United's share price up by 14%.

Schoenebaum was also quick to qualify the excitement, noting that the FDA only provided a "small" approval--helping a portion of patients get some exercise--on data for a 6-minute walk test. But even a small amount of revenue, say $100 million, is a gift at this stage. And United has an ongoing study for the drug that could make it much, much more competitive in the field.

Joseph Schwartz at Leerink estimated peak sales at $250 million, but also added that for now much of that cash will come when doctors switch over patients currently on "subcutaneous, intravenous, or inhaled treprostinil."

SI, ME REFIERO A "opciones"

Hasta 2 rechazos y un tercer intento sin datos adicionales y lo consiguen!
Esto de la FDA menuda casa de putas ...

UTHR

:)